Truist Financial Corp Adverum Biotechnologies, Inc. Transaction History

Truist Financial Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 05, 2021	SELL	$2.08 - $3.6 $53,040 - $91,800	-25,500 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$3.36 - $10.56 $23,520 - $73,920	-7,000 Reduced 21.54%	25,500 $89,000
Q4 2020 Nov 19, 2021	SELL	$9.84 - $14.26 $63,310 - $91,748	-6,434 Reduced 16.53%	32,500 $352,000
Q4 2020 Feb 18, 2021	BUY	$9.84 - $14.26 $63,310 - $91,748	6,434 Added 19.8%	38,934 $422,000
Q3 2020 Nov 13, 2020	BUY	$10.3 - $21.64 $175,100 - $367,880	17,000 Added 109.68%	32,500 $335,000
Q4 2019 Feb 14, 2020	BUY	$5.12 - $12.22 $79,360 - $189,410	15,500 New	15,500 $179,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.